StockpollyBeta
Get App
Popularity #4,218
CRVO · NASDAQ · Biotechnology

CervoMed (CRVO)

Develops neflamapimod for age-related brain disorders.

$2.56
After hours+0.02 (+0.79%)
At close$2.54(+5.39%)

  1. CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

    GlobeNewsWire

  2. CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

    GlobeNewsWireClinical

  3. CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

    GlobeNewsWire

  4. CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

    GlobeNewsWire

  5. CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

    GlobeNewsWire

  6. CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

    GlobeNewsWire

  7. CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

    GlobeNewsWire

  8. CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042

    GlobeNewsWire

  9. CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

    GlobeNewsWire

  10. CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies

    GlobeNewsWire

  11. CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates

    Globe News Wire

  12. CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates

    GlobeNewsWire

  13. CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

    GlobeNewsWire

  14. CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

    GlobeNewsWire

  15. CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

    GlobeNewsWire

  16. CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates

    Zacks Investment Research

  17. CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

    GlobeNewsWire

  18. CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

    GlobeNewsWire

  19. CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

    GlobeNewsWire

  20. CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates

    Zacks Investment Research